BMB Reports

Korean Society for Biochemistry and Molecular Biology (생화학분자생물학회)
권호 표지
DOI QR코드

DOI QR Code

USP14 inhibition regulates tumorigenesis by inducing apoptosis in gastric cancer

  • Mi Yea Lee (Department of Biomedical Sciences, Asan Medical Center, University of Ulsan College of Medicine) ;
  • Min-Jee Kim (Department of Biomedical Sciences, Asan Medical Center, University of Ulsan College of Medicine) ;
  • Jun-O Jin (Lung Cancer Research Center, Asan Medical Center, University of Ulsan College of Medicine) ;
  • Peter Chang-Whan Lee (Department of Biomedical Sciences, Asan Medical Center, University of Ulsan College of Medicine)
  • Received : 2023.04.24
  • Accepted : 2023.06.26
  • Published : 2023.08.31
Download PDF
⟨ Previous Next ⟩

Abstract

Deubiquitinases (DUBs) are an essential component of the ubiquitin-proteasome system (UPS). They trim ubiquitin from substrate proteins, thereby preventing them from degradation, and modulate different cellular processes. Ubiquitin-specific protease 14 (USP14) is a DUB that has mainly been studied for its role in tumorigenesis in several cancers. In the present study, we found that the protein levels of USP14 were remarkably higher in gastric cancer tissues than in the adjacent normal tissues. We also demonstrated that the inhibition of USP14 activity using IU1 (an USP14 inhibitor) or the inhibition of USP14 expression using USP14-specific siRNA markedly reduced the viability of gastric cancer cells and suppressed their migratory and invasive abilities. The reduction in gastric cancer cell proliferation due to the inhibition of USP14 activity was a result of the increase in the degree of apoptosis, as evidenced by the increased expression levels of cleaved caspase-3 and cleaved PARP. Furthermore, an experiment using the USP14 inhibitor IU1 revealed that the inhibition of USP14 activity suppressed 5-fluorouracil (5-FU) resistance in GC cells. Collectively, these findings indicate that USP14 plays critical roles in gastric cancer progression and suggest its potential to serve as a novel therapeutic target for gastric cancer treatment.

Keywords

Acknowledgement

This research was supported by the Basic Research Program through the National Research Foundation of Korea (NRF) funded by MSIT (RS-2023-00208173, RS-2023-00207868).

References

  1. Thrift AP and Nguyen TH (2021) Gastric cancer epidemiology. Gastrointest Endosc Clin N Am 31, 425-439 https://doi.org/10.1016/j.giec.2021.03.001
  2. Alsina M, Arrazubi V, Diez M and Tabernero J (2023) Current developments in gastric cancer: from molecular profiling to treatment strategy. Nat Rev Gastroenterol Hepatol 20, 155-170 https://doi.org/10.1038/s41575-022-00703-w
  3. Al-Batran SE, Homann N, Pauligk C et al (2019) Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial. Lancet 393, 1948-1957 https://doi.org/10.1016/S0140-6736(18)32557-1
  4. Di Martino M, Primavesi F, Syn N et al (2021) Perioperative chemotherapy versus surgery alone for resectable colorectal liver metastases: an international multicentre propensity score matched analysis on long-term outcomes according to established prognostic risk scores. HPB (Oxford) 23, 1873-1885 https://doi.org/10.1016/j.hpb.2021.04.026
  5. Smyth EC, Verheij M, Allum W et al (2016) Gastric cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 27, v38-v49 https://doi.org/10.1093/annonc/mdw350
  6. Viale PH (2020) The American cancer society's facts & figures: 2020 edition. J Adv Pract Oncol 11, 135-136
  7. Harrigan JA, Jacq X, Martin NM and Jackson SP (2018) Deubiquitylating enzymes and drug discovery: emerging opportunities. Nat Rev Drug Discov 17, 57-78 https://doi.org/10.1038/nrd.2017.152
  8. Peth A, Besche HC and Goldberg AL (2009) Ubiquitinated proteins activate the proteasome by binding to Usp14/Ubp6, which causes 20S gate opening. Mol Cell 36, 794-804 https://doi.org/10.1016/j.molcel.2009.11.015
  9. Komander D, Clague MJ and Urbe S (2009) Breaking the chains: structure and function of the deubiquitinases. Nat Rev Mol Cell Biol 10, 550-563 https://doi.org/10.1038/nrm2731
  10. Kwon YT and Ciechanover A (2017) The ubiquitin code in the ubiquitin-proteasome system and autophagy. Trends Biochem Sci 42, 873-886 https://doi.org/10.1016/j.tibs.2017.09.002
  11. Sun T, Liu Z and Yang Q (2020) The role of ubiquitination and deubiquitination in cancer metabolism. Mol Cancer 19, 146
  12. Han S, Wang R, Zhang Y et al (2022) The role of ubiquitination and deubiquitination in tumor invasion and metastasis. Int J Biol Sci 18, 2292-2303 https://doi.org/10.7150/ijbs.69411
  13. Lee CS, Kim S, Hwang G and Song J (2021) Deubiquitinases: modulators of different types of regulated cell death. Int J Mol Sci 22, 4352
  14. Jolly LA, Kumar R, Penzes P, Piper M and Gecz J (2022) The DUB club: deubiquitinating enzymes and neurodevelopmental disorders. Biol Psychiatry 92, 614-625 https://doi.org/10.1016/j.biopsych.2022.03.022
  15. Liu Y, Xu J, Wang Y et al (2022) USP14 regulates cell cycle progression through deubiquitinating CDK1 in breast cancer. Acta Biochim Biophys Sin (Shanghai) 54, 1610-1618 https://doi.org/10.3724/abbs.2022160
  16. Schwertman P, Bekker-Jensen S and Mailand N (2016) Regulation of DNA double-strand break repair by ubiquitin and ubiquitin-like modifiers. Nat Rev Mol Cell Biol 17, 379-394 https://doi.org/10.1038/nrm.2016.58
  17. An T, Lu Y, Gong Z et al (2022) Research progress for targeting deubiquitinases in gastric cancers. Cancers (Basel) 14, 5831
  18. Zhu Y, Zhang C, Gu C, Li Q and Wu N (2016) Function of deubiquitinating enzyme USP14 as oncogene in different types of cancer. Cell Physiol Biochem 38, 993-1002 https://doi.org/10.1159/000443051
  19. Han KH, Kwak M, Lee TH et al (2019) USP14 inhibition regulates tumorigenesis by inducing autophagy in lung cancer in vitro. Int J Mol Sci 20, 5300
  20. Yang JS, Yoon N, Kong M, Jung BH, Lee H and Park J (2021) USP14 regulates cancer cell growth in a fatty acid synthase-independent manner. Int J Mol Sci 22, 13437
  21. Fu Y, Ma G, Liu G et al (2018) USP14 as a novel prognostic marker promotes cisplatin resistance via Akt/ERK signaling pathways in gastric cancer. Cancer Med 7, 5577-5588 https://doi.org/10.1002/cam4.1770
  22. Chen XY, Liang R, Yi YC et al (2021) The m(6)A reader YTHDF1 facilitates the tumorigenesis and metastasis of gastric cancer via USP14 translation in an m(6)A-dependent manner. Front Cell Dev Biol 9, 647702
  23. Petryszyn P, Chapelle N and Matysiak-Budnik T (2020) Gastric cancer: where are we heading? Dig Dis 38, 280-285 https://doi.org/10.1159/000506509
  24. Pasechnikov V, Chukov S, Fedorov E, Kikuste I and Leja M (2014) Gastric cancer: prevention, screening and early diagnosis. World J Gastroenterol 20, 13842-13862 https://doi.org/10.3748/wjg.v20.i38.13842
  25. Song Z, Wu Y, Yang J, Yang D and Fang X (2017) Progress in the treatment of advanced gastric cancer. Tumour Biol 39, 1010428317714626
  26. Chen VC, Huang JY, Tzang BS, Hsu TC and McIntyre RS (2022) Synergistic effects of the combinational use of escitalopram oxalate and 5-fluorouracil on the inhibition of gastric cancer SNU-1 cells. Int J Mol Sci 23, 16179
  27. Liu B, Chen J and Zhang S (2019) Emerging role of ubiquitin-specific protease 14 in oncogenesis and development of tumor: therapeutic implication. Life Sci 239, 116875
  28. He F, Chen Y, He D and He S (2023) USP14-mediated deubiquitination of SIRT1 in macrophage promotes fatty acid oxidation amplification and M2 phenotype polarization. Biochem Biophys Res Commun 646, 19-29 https://doi.org/10.1016/j.bbrc.2022.12.076
  29. Zhu L, Yang S, He S et al (2016) Downregulation of ubiquitin-specific protease 14 (USP14) inhibits breast cancer cell proliferation and metastasis, but promotes apoptosis. J Mol Histol 47, 69-80 https://doi.org/10.1007/s10735-015-9650-3
  30. Zhu Y, Zhang Y, Sui Z, Zhang Y, Liu M and Tang H (2017) USP14 de-ubiquitinates vimentin and miR-320a modulates USP14 and vimentin to contribute to malignancy in gastric cancer cells. Oncotarget 8, 48725-48736 https://doi.org/10.18632/oncotarget.10706
  31. Kim DS, Min K and Lee SK (2020) Cell cycle dysregulation is associated with 5-fluorouracil resistance in gastric cancer cells. Anticancer Res 40, 3247-3254 https://doi.org/10.21873/anticanres.14306
  32. Kang BW, Kim JG, Kwon OK, Chung HY and Yu W (2014) Non-platinum-based chemotherapy for treatment of advanced gastric cancer: 5-fluorouracil, taxanes, and irinotecan. World J Gastroenterol 20, 5396-5402 https://doi.org/10.3748/wjg.v20.i18.5396
  33. Longley DB, Harkin DP and Johnston PG (2003) 5-fluorouracil: mechanisms of action and clinical strategies. Nat Rev Cancer 3, 330-338
  34. Azwar S, Seow HF, Abdullah M, Faisal Jabar M and Mohtarrudin N (2021) Recent updates on mechanisms of resistance to 5-fluorouracil and reversal strategies in colon cancer treatment. Biology (Basel) 10, 854